Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00884520 · ClinicalTrials.gov registry record · Early Phase 1

An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037

A Early Phase 1 study, sponsored by Siemens Molecular Imaging.

Completed
Registry status
Early Phase 1
Development phase
16
Enrollment target

NCT00884520: Completed Early Phase 1 study, sponsored by Siemens Molecular Imaging.

NCT00884520 is a Early Phase 1 study that has completed, run by Siemens Molecular Imaging. The registered enrollment target is 16 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00884520, a Early Phase 1 study, has completed, sponsored by Siemens Molecular Imaging.

COMPLETED
Registry status
Early Phase 1
Development phase
16 participants
Enrollment target

Study Summary

Phase: Exploratory Study Objectives: To collect drug bio-distribution data, begin collection of baseline and tumor/background imaging data, acquire experience to improve study design and the conduct of future studies Design: Exploratory, open label, nonrandomized, multi-center study Duration: Three visits - one screening, one imaging, and one follow-up visit at 24 hours post-dose Procedures: Informed consent, collection of demographic information and medical history, physical examinations, vital signs, 12-lead ECGs, routine blood tests to assess major organ functions, complete blood counts and clinical chemistries for safety, blood sample for CA-IX assay, pre-dose and post-dose blood samples for metabolite analysis, dosing with \[F-18\]VM4-037, PET imaging scan, dosimetry estimation (normals), urine collections (normals), tumor immunohistochemistry with CA-IX biomarker, follow up to imaging to collect adverse events Subjects: Approximately sixteen (16) adult subjects including four (4) healthy volunteers and twelve (12) cancer subjects who have confirmed or highly suspected diagnosis of head \& neck, lung, large solitary hepatic and renal cell cancer, as defined by protocol criteria

Interventions

  • DRUG [F-18] VM4-037

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2009-04
Est. Completion 2010-03
Phase Early Phase 1
Siemens Molecular Imaging

9 total trials

What the finished NCT00884520 record still lists

NCT00884520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 1 intervention - of which [F-18] VM4-037 is the first listed.

NCT00884520 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00884520 about?

NCT00884520 is a clinical study titled "An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037". Phase: Exploratory Study Objectives: To collect drug bio-distribution data, begin collection of baseline and tumor/background imaging data, acquire experience to improve study design and the conduct of future studies Design: Exploratory, open label, nonrandomized, multi-center study Duration: Thr...

What is the current status of trial NCT00884520?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2009-04. Estimated completion is 2010-03.

What interventions are being tested in trial NCT00884520?

The interventions under investigation include: [F-18] VM4-037 (DRUG).

Who is sponsoring clinical trial NCT00884520?

This trial is sponsored by Siemens Molecular Imaging, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00884520's enrollment target sits among peer trials

16 1370th of 2000 higher than 598 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00884520, the US trial registry maintained by the National Library of Medicine. NCT00884520 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.